Body Mass Index as a Potential Confounder in Dutasteride and Fertility Studies

The letter to the editor discusses the potential oversight of body mass index (BMI) as a confounding factor in a study by Kim et al. on the long-term use of dutasteride for treating androgenic alopecia and its impact on semen quality. The authors argue that obesity and higher BMI are independently associated with impaired semen parameters and hormonal profiles, which could interact with the effects of dutasteride. The absence of BMI data in the study raises concerns that metabolic health differences might have influenced the observed decline in semen quality. The authors recommend including BMI as a covariate in future research to improve the validity of findings regarding the reproductive safety of long-term dutasteride use.